With 1.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 33660.0 shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $2.1399 whereas the lowest price it dropped to was $2.02. The 52-week range on STRR shows that it touched its highest point at $4.63 and its lowest point at $1.72 during that stretch. It currently has a 1-year price target of $12.00. STRR paid its most recent dividend on 1534291200, while the ex-dividend date for that was 1534291200. Beta for the stock currently stands at 1.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of STRR was down-trending over the past week, with a drop of -2.74%, but this was down by -0.93% over a month. Three-month performance dropped to -1.84% while six-month performance fell -3.84%. The stock lost -5.75% in the past year, while it has lost -52.24% so far this year. A look at the trailing 12-month EPS for STRR yields -1.37 with Next year EPS estimates of -0.35. For the next quarter, that number is -0.20. This implies an EPS growth rate of 104.52% for this year and -336.67% for next year.
Float and Shares Shorts:
At present, 3.23 million STRR shares are outstanding with a float of 1.98 million shares on hand for trading. On 2025-07-31, short shares totaled 8014.0, which was 25.0 higher than short shares on 1751241600. In addition to Mr. Jeffrey E. Eberwein as the firm’s Executive Chairman of the Board, Mr. Richard Kenneth Coleman Jr. serves as its Chief Executive Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, STRR reported revenue of $23708000.0 and operating income of -$952000.0. The EBITDA in the recently reported quarter was $512000.0 and diluted EPS was $0.86.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With STRR analysts setting a high price target of 12.0 and a low target of 12.0, the average target price over the next 12 months is 12.0. Based on these targets, STRR could surge 463.38% to reach the target high and rise by 463.38% to reach the target low. Reaching the average price target will result in a growth of 463.38% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.21052 being high and -$3.34948 being low. For STRR, this leads to a yearly average estimate of -$3.28. The surprise factor in the prior quarter was -$0.25. Based on analyst estimates, the high estimate for the next quarter is -$0.33 and the low estimate is -$0.33. The average estimate for the next quarter is thus -$0.33.
